COMPANY PROFILE

Bionoxx

Explore full profile

Pioneering oncolytic virus development for advanced cancer immunotherapy solutions

Seoul, South KoreaFounded 2016

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bionoxx

Bionoxx operates in the biopharmaceutical sector, focusing on the development of oncolytic viruses for cancer immunotherapy. The company leverages extensive expertise in medical research and clinical trials to engineer and evaluate innovative treatments targeting cancer cells. Bionoxx serves healthcare providers and research institutions, aiming to enhance therapeutic options for cancer patients. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potential commercialization of successful therapies. The company is led by experienced professionals with a strong background in medical research and clinical studies, particularly in the field of oncolytic virus development. Bionoxx's market presence is primarily in the medical and scientific communities, where it contributes to advancing cancer treatment methodologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Seoul, South Korea
Employees: 11
Open positions: None listed
Dealroom signal: 32.0/100
Business model: Manufacturing
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Oct 2022	$16M	$64M	Yuanta Investment · Daekyo Investment	↗
OtherOther financing	Jan 2018	$0	—	DADAM Investment	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Bionoxx website traffic

Latest recorded traffic for Bionoxx is 180 monthly website visits, down 95.5% over the last three months. Bionoxx's team declined 15.4% over the past year.

Latest monthly visits180 3-month web change-95.5% 1-year team growth-15.4%

Monthly website visitsApr 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

YIYuanta Investment
DIDaekyo Investment

Other known investors1 additional known investor

DIDADAM Investment

Talent

Book a demo to see the people

Employees 11 total headcount

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

1 countries with
team presence

🇰🇷 South Korea100%

1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bionoxx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bionoxx’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.